Lenalidomide is an analogue of the immunomodulatory drug thalidomide with increased potency and fewer adverse effects. It is used in the treatment of hematologic and solid cancers due to its antitumor and anti-angiogenic activities.
|Mechanism of Action||Lenalidomide has been shown to inhibit production of pro inflammatory cytokines TNF-α, IL-1, IL-6, IL-12 and elevate the production of anti-inflammatory cytokine IL-10.|
|References||Kotla, V., Goel, S., Nischal, S., Heuck, C., Vivek, K., Das, B., & Verma, A. (2009). Mechanism of action of lenalidomide in hematological malignancies. Journal of Hematology & Oncology, 2(1), 36. doi:10.1186/1756-8722-2-36|